COST-EFFECTIVENESS OF SUBCUTANEOUS VERSUS INTRAMUSCULAR INTERFERON BETA-1A IN PORTUGAL BASED ON THE FINDINGS OF COCHRANE COLLABORATION REVIEW OF FIRST-LINE TREATMENTS FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS

被引：0
|
作者：
Silverio, N. [1 ]
Sequeira, L. [1 ]
Meletiche, D. [2 ]
机构：
[1] Merck SA, Alges, Portugal
[2] EMD Serono, Rockland, ME USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.897
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND43
引用
收藏
页码：A398 / A398
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of peginterferon beta-1a in Italian relapsing remitting multiple sclerosis management
    Iannazzo, Sergio
    Santoni, Laura
    Saleri, Cecilia
    Puma, Elisa
    Vestri, Giulia
    Giuliani, Luigi
    Canonico, Pier Luigi
    Centonze, Diego
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2016, 17 : 13 - 36
  • [32] COST-EFFECTIVENESS ANA LYSES OF NATALIZUMAB FOR 1ST LINE VERSUS INTERFERON BETA-1A 44 MCG IN THE TREATMENT OF HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS IN BRAZIL
    Nishikawa, A. M.
    Paladini, L.
    Liamas, A. L.
    Bueno, C. C.
    Clark, O. A. C.
    VALUE IN HEALTH, 2013, 16 (07) : A721 - A722
  • [33] No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study
    Kappos, Ludwig
    Havrdova, Eva
    Giovannoni, Gavin
    Khatri, Bhupendra O.
    Gauthier, Susan A.
    Greenberg, Steven J.
    You, Xiaojun
    Wang, Ping
    Giannattasio, Giorgio
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (13) : 1736 - 1747
  • [34] Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis
    Hashemi-Meshkini, Am Ir
    Zekri, Hedieh Sadat
    Karimi-Yazdi, Hasan
    Zaboli, Pardis
    Sahraian, Mohammad Ali
    Nikfar, Shekoufeh
    IRANIAN JOURNAL OF NEUROLOGY, 2018, 17 (03) : 123 - 128
  • [35] Quality of life in 1000 patients with relapsing-remitting multiple sclerosis and the impact of treatment initiation with intramuscular interferon beta-1a
    Putzki, Norman
    Hartung, Hans Peter
    MULTIPLE SCLEROSIS, 2008, 14 : S149 - S149
  • [36] Estimating Net Health Benefits of Intramuscular Interferon Beta-1a and Fingolimod in Treating Patients with Relapsing-Remitting Multiple Sclerosis
    Szabo, Shelagh
    Dembek, Carole
    Moore, Peter
    White, Leigh Ann
    Wijaya, Hardy
    Levy, Adrian
    NEUROLOGY, 2012, 78
  • [37] ESTIMATING NET HEALTH BENEFITS OF INTRAMUSCULAR INTERFERON BETA-1A AND FINGOLIMOD IN TREATING PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Szabo, S. M.
    Dembek, C.
    Moore, P.
    White, L. A.
    Wijaya, H.
    Levy, A. R.
    VALUE IN HEALTH, 2011, 14 (07) : A317 - A317
  • [38] COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON BETA-1A VS. FIRST LINE INJECTABLE DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Ruiz, L.
    Toro-Diaz, H.
    Cele, C.
    Hernandez, L.
    Harrington, A.
    VALUE IN HEALTH, 2017, 20 (09) : A723 - A723
  • [39] Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: Further outcomes from the IMPROVE study
    De Stefano, Nicola
    Sormani, Maria Pia
    Stubinski, Bettina
    Blevins, Gregg
    Drulovic, Jelena S.
    Issard, Delphine
    Shotekov, Penko
    Gasperini, Claudio
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2012, 312 (1-2) : 97 - 101
  • [40] Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis
    Liu, Ying
    Vollmer, Timothy
    Havrdova, Eva
    Riester, Katherine
    Lee, Andrew
    Phillips, Glenn
    Wang, Ping
    Sabatella, Guido
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 11 : 18 - 24
12345